NEWTON, Mass.--(BUSINESS WIRE)--Novelos Therapeutics, Inc. (OTCBB: NVLT), a biopharmaceutical company focused on the development of therapeutics to treat cancer and hepatitis, today announced the appointment of James S. Manuso, Ph.D., to Novelos’ board of directors. Dr. Manuso, Chairman, President and CEO of SuperGen, Inc. (NASDAQ: SUPG), has over 30 years of expertise in life sciences senior management, product commercialization, partnering, financing, venture management and consulting. His appointment increases the number of directors to seven, five of which are independent directors.
